Monocyclic oga inhibitor compounds

A compound and selected technology, applied in organic chemistry, drug combination, nervous system diseases, etc., can solve problems such as cell cycle arrest and glycogen mobilization defects
CN110300752AInactive Publication Date: 2019-10-01JANSSEN PHARMA NV
12 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN ยท China
Patent Type
Applications(China)
Current Assignee / Owner
JANSSEN PHARMA NV
Publication Date
2019-10-01
Estimated Expiration
Not applicable ยท inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compoundsand compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to O-GlcNAc hydrolase (OGA) inhibitor having the structure shown in formula (I)

[0002]

[0003] wherein these groups are as defined in the specification. The present invention also relates to pharmaceutical compositions comprising such compounds, to processes for the preparation of such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, Such disorders are for example tauopathies, especially Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by tauopathies, especially amyotrophic lateral sclerosis or frontal sclerosis caused by C9ORF72 mutations temporal lobe dementia. Background technique

[0004] O-GlcNAcylation is a reversible modification of proteins in which N-acetyl-D-glucosamine residues are transferred to the hydroxyl groups of serine and threonine r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More